CRNX - Crinetics Pharmaceuticals, Inc.
| Previous Close | 17.74 |
| Open | 17.61 |
| Bid | 16.88 x 2200 |
| Ask | 17.23 x 800 |
| Day's Range | 16.85 - 18.09 |
| 52 Week Range | 16.80 - 42.00 |
| Volume | 24,943 |
| Avg. Volume | 69,934 |
| Market Cap | 408.98M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings Date | Mar 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.50 |
- Zacks
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -13.33% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- Simply Wall St.
If You Had Bought Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock A Year Ago, You'd Be Sitting On A 14% Loss, Today
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
- GlobeNewswire
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it would receive up to approximately $0.9 million in continued funding under its Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) of the National Institutes of Health (NIH). The funds are being used to support the ongoing research and development of Crinetics’ nonpeptide somatostatin agonists for congenital hyperinsulinemias (CHI).
- GlobeNewswire
Crinetics Pharmaceuticals Appoints Stephanie Okey to Board of Directors
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Stephanie S. Okey, M.S. to its board of directors as an independent board member. “Stephanie’s extensive experience with the regulatory approval process, launch and commercialization of rare and orphan disease products makes her a valuable addition to our board,” said Scott Struthers, Ph.D., President and Chief Executive Officer of Crinetics.
- GlobeNewswire
Crinetics Pharmaceuticals Initiates Phase 1 Study of CRN01941 for the Treatment of Neuroendocrine Tumors
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single- and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN01941 in healthy volunteers. CRN01941 is an oral nonpeptide somatostatin receptor subtype 2 (sst2) biased agonist designed for the treatment of neuroendocrine tumors (NETs) that originate from neuroendocrine cells commonly found in the gut, lung, or pancreas.
- GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, May 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the dosing of the first patients in the ACROBAT EVOLVE and EDGE trials for CRN00808 in patients with acromegaly. EVOLVE is a double-blind, placebo-controlled, randomized withdrawal study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, in patients with acromegaly that are responders to octreotide LAR or lanreotide depot monotherapy. EDGE is an open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 in patients with acromegaly whose disease is inadequately controlled by octreotide LAR or lanreotide depot alone.
- GlobeNewswire
Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning
SAN DIEGO, March 18, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO2019
SAN DIEGO, March 14, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
SAN DIEGO, March 13, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
Crinetics Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 21, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 02, 2019 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
SAN DIEGO, Nov. 20, 2018 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
- GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 13, 2018 -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization.
